Study to compare Pharmacokinetics & Pharmacodynamics of Warfarin & Esmolol in the Absence & Presence of MEDI0382

Exclusion Criteria

• - Any concurrent condition that in the opinion of the investigator would interfere with the evaluation of the investigational product.
• - Receipt of investigational product as part of a clinical study or a glucagon-like peptide 1 (GLP-1) analogue containing preparation within the last 30 days or 5 half-lives of the drug (whichever is longer) at the time of screening.
• - Concurrent participation in another study of any kind.
• - Severe allergy/hypersensitivity to any of the proposed study treatments or excipients.
• - History or presence of gastrointestinal (GI), hepatic, or renal disease or any other conditions known to interfere with absorption, distribution, metabolism or excretion of drugs.
• - Impaired renal function is defined as estimated glomerular filtration rate (eGFR) < 60 mL/minute/1.73 m^2 at screening.
• - Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of screening.
• - History of hemophilia, von Willebrand’s disease, lupus anticoagulant, or other diseases/syndromes that can either alter or increase the propensity for bleeding.